RVTY

Revvity Inc

163.48

Nov 03 • 3:59 PM ET +11.88 (7.84%)

166.50

Aftermarket • 6:59 PM ET +3.02 (1.85%)

Healthcare Diagnostics & Research USA Large NYSE

Today, 10:41 AMRevvity beats Q3 estimates with EPS $1.38, revenue $709.6M, raises 2026 pro forma EPS outlook to $5.40–$5.45 and revenue to ~$2.86B

Peers: DHR A QGEN TMO BIO WAT MTD TECH ILMN BRKR

| Held by: VTI VOO VB VBR RSP IVV SPY DFAT XLV TCAF

Scroll to Statements

Index	S&P 500
Market Cap	18.24B
Enterprise Value	20.41B
Income	253.74M
Sales	2.94B
Book/sh	64.78
Cash/sh	5.32
Dividend Est.	0.28 (0.17%)
Dividend TTM	0.28 (0.17%)
Dividend Ex-Date	Jan 22, 2027
Dividend Gr. 3/5Y	0.00% 0.00%
Payout	13.49%
Employees	11000
IPO	Jul 06, 1965

P/E	72.37
Forward P/E	27.67
PEG	3.30
P/S	6.20
P/B	2.52
P/C	30.74
P/FCF	31.01
EV/EBITDA	23.54
EV/Sales	6.94
Quick Ratio	2.10
Current Ratio	2.65
Debt/Eq	0.38
LT Debt/Eq	0.38
Option/Short	Yes / Yes

EPS (ttm)	2.26
EPS next Y	5.91
EPS next Q	1.61
EPS this Y	6.20%
EPS next Y	9.93%
EPS next 5Y	8.38%
EPS past 3/5Y	-22.75% -20.40%
Sales past 3/5Y	-4.82% -5.47%
EPS Y/Y TTM	-10.40%
Sales Y/Y TTM	4.56%
EPS Q/Q	37.73%
Sales Q/Q	4.29%
Earnings	Nov 03 BMO
EPS/Sales Surpr.	6.42% 2.14%

Insider Own	0.47%
Insider Trans	-1.71%
Inst Own	104.36%
Inst Trans	6.45%
ROA	2.15%
ROE	3.46%
ROIC	2.53%
Gross Margin	47.97%
Oper. Margin	15.44%
Profit Margin	8.63%
SMA20	4.29%
SMA50	12.10%
SMA200	45.55%
Trades

Shs Outstand	111.59M
Shs Float	111.06M
Short Float	5.76%
Short Ratio	3.42
Short Interest	6.39M
52W High	169.06 -3.30%
52W Low	81.22 101.28%
Volatility	4.45% 4.12%
ATR (14)	7.25
RSI (14)	60.50
Beta	1.09
Rel Volume	1.80
Avg Volume	1.87M
Volume	3,372,929

Perf Week	1.00%
Perf Month	3.89%
Perf Quarter	42.13%
Perf Half Y	77.12%
Perf YTD	68.97%
Perf Year	75.84%
Perf 3Y	85.44%
Perf 5Y	-6.09%
Perf 10Y	225.85%
Recom	2.57
Target Price	157.43
Prev Close	151.60
Price	163.48
Change %	7.84%

Consensus

Hold

Avg. Price Target

$157.43

Implied Upside

-3.7%

Analysts13incl. previous ratings

Rating Distribution3 Buy · 10 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Oct 06, 2026	Initiated	WWilliam Blair	Outperform
Sep 09, 2026	Resumed	UUBS	Neutral	$140	-14.4%
Sep 01, 2026	Initiated	RRBC Capital Mkts	Sector Perform	$135	-17.4%
Jun 26, 2026	Resumed	BBernstein	Mkt Perform	$115	-29.7%
Jun 02, 2026	Resumed	WWolfe Research	Peer Perform
Apr 14, 2026	Downgrade	BBarclays	Overweight → Equal Weight	$95	-41.9%
Dec 15, 2025	Downgrade	BBofA Securities	Buy → Neutral	$110	-32.7%
Dec 09, 2025	Initiated	GGoldman	Neutral	$105	-35.8%
Oct 16, 2025	Initiated	GGuggenheim	Neutral
May 01, 2025	Upgrade	UUBS	Neutral → Buy	$115	-29.7%
Jan 10, 2025	Downgrade	BBernstein	Outperform → Mkt Perform	$130	-20.5%
Dec 13, 2024	Upgrade	BBofA Securities	Neutral → Buy	$138	-15.6%
Oct 15, 2024	Upgrade	BBarclays	Equal Weight → Overweight	$125 → $140	-14.4%
Aug 28, 2024	Initiated	WWells Fargo	Equal Weight	$130	-20.5%
Jul 08, 2024	Initiated	LLeerink Partners	Outperform	$125	-23.5%
Jun 03, 2024	Resumed	JJefferies	Hold	$115	-29.7%
Jan 16, 2024	Downgrade	UUBS	Buy → Neutral	$105 → $125	-23.5%
Jan 04, 2024	Upgrade	EEvercore ISI	In-line → Outperform	$88 → $125	-23.5%
Dec 19, 2023	Initiated	WWells Fargo	Equal Weight	$95	-41.9%
Dec 13, 2023	Initiated	WWolfe Research	Peer Perform

Today 04:30PM	Revvity Inc. stock outperforms competitors on strong trading day (MarketWatch) +7.84%
09:45AM	Revvity Shares Jump Nearly 6% as Q3 Earnings Beat Forecasts and 2026 Guidance Improves (InvestorsHub)
09:17AM	Revvity Faced Off With 'Elevated Investor Expectations' - And Won (Investor's Business Daily)
09:08AM	Revvity Beats As Life Sciences Swings Back To Growth, But Q4 Guide Shows Some Of Q3 Was Borrowed (Earnings Whispers)
06:11AM	Revvity: Q3 Earnings Snapshot (Associated Press)
05:00AM	Loading…
05:00AM	Revvity Announces Financial Results for the Third Quarter of 2026 (Business Wire)
Oct-30-26 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire) -5.30%
Oct-26-26 05:33PM	After A 39% Rally, Revvity Must Turn Its Record Instrument Backlog Into Third-Quarter Shipments (Earnings Whispers)
Oct-20-26 08:00AM	Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows (Business Wire)
Oct-13-26 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Oct-06-26 08:00AM	Revvity to Host Investor Day (Business Wire)
Oct-02-26 08:00AM	Revvity to Hold Earnings Call on November 3, 2026 (Business Wire)
Sep-24-26 04:30PM	Revvity Inc. stock outperforms competitors on strong trading day (MarketWatch) +6.03%
08:00AM	Revvity Launches IVDR-Certified Solution for Early Detection of Type 1 Diabetes (Business Wire)
Sep-15-26 04:30PM	Revvity Inc. stock outperforms competitors on strong trading day (MarketWatch) +9.11%
06:00AM	Loading…
Sep-09-26 06:00AM	Revvity to Acquire Human Cell Design to Advance Human-Relevant Cell Models for Metabolic Disease Drug Discovery (Business Wire)
Aug-11-26 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Aug-04-26 03:03PM	Revvity Inc (RVTY) (Q2 2026) Earnings Call Highlights: Strong Diagnostics Growth and Raised ... (GuruFocus.com)
08:23AM	Revvity Tops Second-Quarter Estimates and Lifts Full-Year Outlook (InvestorsHub)
06:11AM	Revvity: Q2 Earnings Snapshot (Associated Press)
06:00AM	Revvity Announces Financial Results for the Second Quarter of 2026 (Business Wire)
Jul-31-26 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
Jul-30-26 02:29PM	Avantor Stock Surged Because One Segment Stopped Shrinking (Trefis)
Jul-20-26 04:30PM	Revvity Inc. stock underperforms Monday when compared to competitors (MarketWatch)
08:00AM	Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure (Business Wire)
Jul-13-26 04:50PM	Alamar Hits A High Note On Alzheimer's Buzz (Trefis)
Jul-08-26 08:00AM	Revvity to Hold Earnings Call on Tuesday, August 4, 2026 (Business Wire)
Jul-01-26 08:00AM	Revvity Expands Signals AI Ecosystem Through Anthropic Claude Integration (Business Wire)
Jun-25-26 04:30PM	Revvity Inc. stock outperforms competitors on strong trading day (MarketWatch) +7.48%
Jun-22-26 08:00AM	Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D (Business Wire)
06:31AM	Loading…
May-05-26 06:31AM	Revvity: Q1 Earnings Snapshot (Associated Press) +6.69%
06:00AM	Revvity Announces Financial Results for the First Quarter of 2026 (Business Wire)
Apr-30-26 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire) +5.30%
Apr-16-26 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Apr-14-26 09:53AM	Tesla upgraded, AppLovin initiated: Wall Street's top analyst calls (The Fly)
Apr-10-26 08:00AM	Revvity to Hold Earnings Call on Tuesday, May 5, 2026 (Business Wire)
Apr-09-26 08:00AM	Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows (Business Wire)
Mar-05-26 07:48AM	Bretton Fund Exited Revvity (RVTY) in 2025 (Insider Monkey)
Mar-04-26 11:30AM	Why Is Revvity (RVTY) Down 5.1% Since Last Earnings Report? (Zacks)
09:20AM	Here's Why You Should Retain Revvity Stock in Your Portfolio for Now (Zacks)
Feb-23-26 07:02AM	Do Wall Street Analysts Like Revvity Stock? (Barchart)
Feb-17-26 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
Feb-05-26 07:45PM	Analyst Report: Revvity, Inc. (Morningstar Research)
08:00AM	Revvity Unveils New High-Impact Discovery Platforms and Showcases Recent Innovations at SLAS2026 (Business Wire)
Feb-03-26 09:50AM	Here's Why Revvity (RVTY) is a Strong Momentum Stock (Zacks) -5.57%
Feb-02-26 02:01PM	Revvity Inc (RVTY) Q4 2025 Earnings Call Highlights: Surpassing EPS Guidance and Strategic ... (GuruFocus.com)
12:52PM	Revvity Q4 Earnings Call Highlights (MarketBeat)
12:44PM	Analyst Report: Revvity, Inc. (Morningstar Research)
10:28AM	Revvity Sees Steady Growth On Rising Demand From Pharma/Biotech Customers (Benzinga)
10:06AM	Do Options Traders Know Something About Revvity Stock We Don't? (Zacks)
09:49AM	Revvity Stock Up as Q4 Earnings Beat, Revenues In Line With Estimates (Zacks)
09:30AM	Revvity (RVTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
07:15AM	Revvity (RVTY) Q4 Earnings and Revenues Beat Estimates (Zacks)
06:29AM	Revvity's (NYSE:RVTY) Q4 CY2025 Sales Beat Estimates (StockStory)
06:21AM	Revvity: Q4 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Fourth Quarter and Full Year of 2025 (Business Wire)
Jan-31-26 10:01PM	Revvity (RVTY) Q4 Earnings: What To Expect (StockStory)
Jan-29-26 12:51PM	Will Revvity Q4 Earnings Benefit From Early Signs of Demand Recovery? (Zacks)
Jan-28-26 09:15AM	Curious about Revvity (RVTY) Q4 Performance? Explore Wall Street Estimates for Key Metrics (Zacks)
07:10AM	Elevance Health (ELV) Beats Q4 Earnings Estimates (Zacks)
Jan-26-26 04:05PM	Revvity Board Declares Quarterly Dividend (Business Wire)
10:00AM	Revvity (RVTY) Earnings Expected to Grow: Should You Buy? (Zacks)
Jan-23-26 12:10PM	Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report? (Zacks)
Jan-21-26 07:58AM	Here's Why You Should Retain Revvity Stock in Your Portfolio for Now (Zacks)
Jan-14-26 06:07AM	Revvity Stock Gains On Solid Early Q4 Results, Upbeat Outlook (Benzinga)
Jan-13-26 06:43PM	Analyst Report: Revvity, Inc. (Morningstar Research) +6.02%
04:35PM	Stocks Fall on Weakness in Software and Credit Card Companies (Barchart)
11:17AM	Stock Indexes Slip as the Magnificent Seven Technology Stocks Retreat (Barchart)
10:14AM	These Stocks Are Todays Movers: JPMorgan, Delta, Intel, AMD, L3Harris, Travere, Revvity, and More (Barrons.com)
09:42AM	Stocks to Watch Tuesday: JPMorgan, Delta, L3Harris (The Wall Street Journal)
05:51AM	Revvity Stock Jumps on Profit Outlook Hike. Why the Shares Are at a Crossroads. (Barrons.com)
05:28AM	Stock Market Today: S&P 500, Dow Jones Futures Slip Ahead Of December CPI Print- JPMorgan, Alphabet, Five9 In Focus (Benzinga)
Jan-12-26 04:15PM	Revvity to Hold Earnings Call on Monday, February 2, 2026; Provides Update on Financial Performance (Business Wire)
08:57AM	RVTY & Eli Lilly Partner to Expand Access to AI Drug Discovery Models (Zacks)
Jan-09-26 08:00AM	Revvity Collaborates with Lilly to Expand Access to AI Drug Discovery Models (Business Wire)
Jan-05-26 04:51AM	What to Expect From Revvitys Q4 2025 Earnings Report (Barchart)
Dec-31-25 07:39AM	Here's Why Diamond Hill Mid Cap Composite Purchased Revvity (RVTY) in Q3 (Insider Monkey)
Dec-22-25 10:37PM	Q3 Earnings Highlights: Revvity (NYSE:RVTY) Vs The Rest Of The Research Tools & Consumables Stocks (StockStory)
Dec-19-25 08:41AM	Revvity Advances AI-Driven Scientific Discovery With Signals Xynthetica (Zacks)
Dec-18-25 08:00AM	Revvity to Present at J.P. Morgan Healthcare Conference (Business Wire)
Dec-17-25 11:04PM	3 Reasons RVTY is Risky and 1 Stock to Buy Instead (StockStory)
Dec-16-25 08:00AM	Revvity Introduces Signals Xynthetica, an AI-Augmented Design Platform for Molecular and Materials Discovery (Business Wire)
Dec-15-25 06:30AM	How Is Revvity's Stock Performance Compared to Other Health Care Stocks? (Barchart)
Dec-09-25 08:16AM	Goldman Sachs starts Life Sciences Tools coverage, rates these 3 stocks at Buy (Investing.com)
Nov-26-25 11:30AM	Revvity (RVTY) Up 9.5% Since Last Earnings Report: Can It Continue? (Zacks)
Nov-19-25 08:35AM	Revvity Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Nov-10-25 07:45AM	Revvity to Acquire ACD/Labs to Expand its Signals Software Capabilities (Business Wire)
Nov-03-25 12:31AM	5 Insightful Analyst Questions From Revvity's Q3 Earnings Call (StockStory)
Oct-28-25 08:00AM	Revvity to Present at Upcoming Investor Conferences (Business Wire)
06:17AM	Company News for Oct 28, 2025 (Zacks)
01:31AM	RVTY Q3 Deep Dive: AI Initiatives and Segment Divergence Shape Outlook (StockStory)
Oct-27-25 03:00PM	Revvity Inc (RVTY) Q3 2025 Earnings Call Highlights: Strong Software Growth and Strategic Share ... (GuruFocus.com)
01:22PM	Analyst Report: Revvity, Inc. (Morningstar Research)
01:10PM	Revvity (RVTY) Stock Trades Down, Here Is Why (StockStory)
10:05AM	RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised (Zacks)
09:30AM	Revvity (RVTY) Reports Q3 Earnings: What Key Metrics Have to Say (Zacks)
07:10AM	Revvity (RVTY) Surpasses Q3 Earnings Estimates (Zacks)
06:18AM	Revvity (NYSE:RVTY) Posts Q3 Sales In Line With Estimates (StockStory)
06:09AM	Revvity: Q3 Earnings Snapshot (Associated Press Finance)
06:00AM	Revvity Announces Financial Results for the Third Quarter of 2025 (Business Wire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Gonzales Anita	VP and CAO	Oct 01 '26	Sale	155.48	84	13,060	7,117	Oct 02 04:05 PM
Gonzales Anita	Officer	Oct 01 '26	Proposed Sale	155.48	84	13,060		Oct 01 10:48 AM
Krakowiak Maxwell	Please See Remarks	Sep 21 '26	Sale	144.53	1,631	235,728	14,781	Sep 23 04:05 PM
Krakowiak Maxwell	Officer	Sep 21 '26	Proposed Sale	144.53	1,631	235,728		Sep 21 10:49 AM
Vohra Tajinder S	Please See Remarks	Sep 16 '26	Sale	140.88	7,330	1,032,650	6,635	Sep 18 04:05 PM
Vohra Tajinder S	Officer	Sep 16 '26	Proposed Sale	140.88	7,330	1,032,650		Sep 16 09:55 AM
Gonzales Anita	Vice President and CAO	Jul 20 '26	Sale	109.48	85	9,306	7,201	Jul 22 04:05 PM
Gonzales Anita	Officer	Jul 20 '26	Proposed Sale	109.48	85	9,306		Jul 20 09:40 AM
Gonzales Anita	Vice President and CAO	Apr 20 '26	Sale	92.80	80	7,424	7,319	Apr 22 04:05 PM
Gonzales Anita	Officer	Apr 20 '26	Proposed Sale	92.80	80	7,424		Apr 20 09:55 AM
Victor Miriame	Please See Remarks	Feb 24 '26	Option Exercise	95.74	1,862	178,268	19,984	Feb 26 04:05 PM
Victor Miriame	Please See Remarks	Feb 24 '26	Sale	97.13	1,862	180,856	18,122	Feb 26 04:05 PM
McMurry-Heath Michelle	Director	Feb 23 '26	Sale	97.26	600	58,356	4,233	Feb 25 04:05 PM
Victor Miriame	Officer	Feb 24 '26	Proposed Sale	97.13	1,862	180,856		Feb 24 11:21 AM
McMurry-Heath Michelle	Director	Feb 23 '26	Proposed Sale	97.26	600	58,353		Feb 23 12:31 PM
Singh Prahlad R.	Please See Remarks	Feb 05 '26	Option Exercise	92.09	25,525	2,350,597	145,738	Feb 06 04:05 PM
Singh Prahlad R.	Please See Remarks	Feb 05 '26	Sale	100.21	25,525	2,557,859	120,213	Feb 06 04:05 PM
Goldberg Joel S	Please See Remarks	Feb 05 '26	Option Exercise	92.09	12,717	1,171,109	55,964	Feb 06 04:05 PM
Goldberg Joel S	Please See Remarks	Feb 05 '26	Sale	100.21	12,717	1,274,357	43,247	Feb 06 04:05 PM
Singh Prahlad R.	Officer	Feb 05 '26	Proposed Sale	100.21	25,525	2,557,886		Feb 05 04:35 PM
Goldberg Joel S	Officer	Feb 05 '26	Proposed Sale	100.21	12,717	1,274,382		Feb 05 04:12 PM
Vohra Tajinder S	Please See Remarks	Feb 02 '26	Option Exercise	92.09	5,756	530,070	16,198	Feb 04 04:05 PM
Vohra Tajinder S	Please See Remarks	Feb 02 '26	Sale	104.50	5,756	601,502	10,442	Feb 04 04:05 PM
Vohra Tajinder S	Officer	Feb 02 '26	Proposed Sale	104.50	5,756	601,502		Feb 02 10:57 AM

Revvity, Inc. provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. It focuses on translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, and informatics. The firm operates through the following segments: Life Sciences and Diagnostics. The Life Sciences segment delivers innovative solutions to optimize workflows, boost productivity, and accelerate drug discovery and development. The Diagnostics segment provides instruments, reagents, assay platforms, and software to healthcare and research professionals, with a focus on reproductive health, immunodiagnostics, emerging market diagnostics, and applied genomics to enhance patient outcomes. Revvity was founded on April 19, 1937 and is headquartered in Waltham, MA.

CEODr. Prahlad R. Singh Ph.D.

Senior VP & CFOMr. Maxwell Krakowiak

Senior Vice President of Global OperationsMr. Tajinder S. Vohra

Senior VP of AdministrationMr. Joel S. Goldberg

Senior Vice President & Chief Business OfficerMs. Miriame Victor

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

RVTY

Revvity Inc

Upgrade your Finviz experience